Cargando…
Neutralizing antibodies for SARS-CoV-2 infection
The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedad Española de Quimioterapia
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717458/ https://www.ncbi.nlm.nih.gov/pubmed/36285851 http://dx.doi.org/10.37201/req/s03.04.2022 |